Research Paper Volume 16, Issue 17 pp 12392—12413
RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway
Figure 10. RPL22L1 can increase the growth of xenograft tumors in vivo. (A) Images of tumors in the control group and siRPL22L1 group. (B) Compared with the control group, the siRPL22L1 group showed a significant decrease in tumor weight. (C) Immunohistochemical images of the control group and siRPL22L1 group. (D) The siRPL22L1 group exhibited a statistically significant reduction in tumor volume when compared to the control group. **, P<0.01.